Thank you, Madam Chair. It's unnecessary, but thank you.
As Mr. Collins said, this is a very interesting panel.
I'm going to begin with BioCanRx. I met with Ms. Michaud of BioCanRx a couple of weeks ago, so I got a bit of a taste of what you've been doing. It sounds very innovative and exciting, a sort of distributed network of science, and applying that science to do very exciting and important things, like changing things for cancer patients.
I have so many questions. I'll begin with Dr. Bell. When we're considering the government investment into this network that includes universities, investigators and private investors, where does the IP from this rest? If we are going to export this, how can Canadian companies benefit from your work?
I'll leave it there.